As of Q2 2023, Amador Bioscience, a next generation CRO that is focused on translational science and early clinical development, has announced the addition of Dr. Lorin Roskos to its Board of Directors. In addition to his position as Chief Scientific Officer (CSO), Dr. Roskos has also served as President of Clinical Quantitative Pharmacology. 
Former Vice President of R&D at AstraZeneca, Dr. Roskos has over 30 years of experience in the field of research and development of innovative drugs.

In a nutshell, Amador Bioscience is a next generation contract research organization that focuses on translational science and early clinical development
His contributions to the field of science and the pharmaceutical industry are highly regarded. He is among the world's first pharmacometricians to explore and advocate the concept of 'translational science' and has been doing so for more than 30 years. Over the course of his career, he has developed extensive management experience within top-tier pharmaceutical companies, as well as experience in research and development.

Source prnewswire